Cytokinetics to Announce Results from BENEFIT-ALS at 66th Annual Meeting of the American Academy of Neurology

Cytokinetics, Incorporated announced today that results from BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS) will be presented during a Platform Session scheduled at the 66th Annual Meeting of the American Academy of Neurology (AAN) to be held April 26 – May 3, 2014 at the Pennsylvania Convention Center in Philadelphia, PA.

The RASCALS Board of Directors Salutes Its Remarkable RASCALS Volunteers

Robert Stehlin and the entire Board of Directors would like to once again recognize the tremendous efforts of our RASCALS Volunteer Army.

Final Results of ALS Phase I Stem Cell Trial Published in Annals of Neurology

The results showed that NSI-566 human spinal cord stem cells can be safely transplanted in both the lumbar and cervical spinal cord segments, did not accelerate disease progression, and warrant further study on dosing and therapeutic efficacy in ALS patients.

Biomarkers Help Predict Progress of ALS

While the size of this study is small, the ability of the specific biomarkers used to predict ALS prognosis suggests that the approach holds promise.

New Gene Variant Discovered for ALS

Research led by King’s College London has identified a new genetic variant, located on chromosome 17, associated with sporadic amyotrophic lateral sclerosis (ALS) – the most common form of motor neurone disease (MND).

New Device Delays Ventilator Need for Some ALS Patients (Op-Ed)

For patients with amyotrophic lateral sclerosis (ALS), the simple act of breathing is often a tough thing to do. Now, these patients have new hope, as a device has been approved by the U.S. Food and Drug Administration (FDA) that may help patients to breathe more easily without a ventilator.

Diaphragm Pacing System Benefits Patients With ALS

Respiratory failure is one of the major complications associated with amyotrophic lateral sclerosis (ALS). The quest for alternative approaches for treating respiratory failure has led to the study, and subsequent FDA approval, of diaphragm pacing for use in ALS patients.

ImStar Selects Lead ALS Drug Candidate for Study by Mid-2014

“We are very excited to announce the selection of IMS-088 as ImStar’s lead ALS compound. As we continue with preclinical development next year, we hope to establish IMS-088 as a safe and effective new drug candidate for ALS,” said Jean-Pierre Julien, ImStar’s chief scientific officer.

Neuraltus’ NP001 Phase 2 Results Highlighted at 24th International Symposium on ALS/MND

According to a post hoc analysis, a greater percentage of patients receiving NP001 experienced a halt in disease progression which reached statistical significance when compared to the combination of concurrent and matched historical (placebo) controls. The high dose of NP001 (2mg/kg) halted progression in 27% of patients compared to 11% of patients on placebo. Further, NP001 was found to be safe and well-tolerated in the study.

ALS TDI and Neurimmune Partner to Advance Treatments for ALS

The ALS Therapy Development Institute (ALS TDI), together with its wholly-owned subsidiary, Anelixis Therapeutics, announced today that it has formed a research partnership with Neurimmune to advance potential treatments for ALS, also known as Lou Gehrig’s disease.